
LENSAR Inc (LNSR) Stock Forecast & Price Target
LENSAR Inc (LNSR) Analyst Ratings
Bulls say
LENSAR is supported by a clear shift toward a higher-margin recurring model, with 3Q26 recurring revenue up 17% Y/Y to $12.6M and representing 89% of total revenue, while procedures rose 12.2% to 52,545 and US FLACS share increased to 24.5%. Its commercial momentum is reinforced by a growing installed base of about 225 ALLY systems, a backlog of 12 systems, and consumable pricing of $239.35 per procedure, all of which point to stronger utilization and durable demand. Even with quarterly lumpiness and a 3Q26 revenue dip to $14.1M, gross margins of about 57.8% and $1.7M of adjusted EBITDA show operating leverage, and the company’s >20% share in the worldwide laser cataract market plus tailwinds from advanced IOL adoption and surgeon preference support long-term growth.
Bears say
LENSAR is viewed negatively because its outlook depends on slower-than-expected uptake of ALLY in the US and outside the US, while FLACS procedure growth also appears less robust. The revenue profile is pressured by lower ALLY pricing, cut from $350k to $280k-$295k per unit and expected to stay there, which contributes to flat revenue in FY26 and declining revenue in FY27 and FY28 despite stable procedural pricing. Seasonal dynamics also imply softer revenue in 3Q26 than 4Q26, and higher operating spend adds further risk to profitability and execution.
This aggregate rating is based on analysts' research of LENSAR Inc and is not a guaranteed prediction by Public.com or investment advice.
LENSAR Inc (LNSR) Analyst Forecast & Price Prediction
Start investing in LENSAR Inc (LNSR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LENSAR Inc (LNSR) Forecast
LENSAR Inc (LNSR) Analyst Forecast & Price Prediction
Start investing in LENSAR Inc (LNSR)
Order type
Buy in
Order amount
Est. shares
0 shares